A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
This study introduces a novel dual-sensitive drug delivery system, gelatin-coated chitosan microparticles (GL-ChMPs), designed to enhance the lung targeting and therapeutic efficacy of semaglutide (SEM). GL-ChMPs were designed to respond to the acidi…
Skeletal muscle is the largest insulin-sensitive tissue in the human body, playing a crucial role in glucose homeostasis, body mobility and overall metabolic health. In obesity and type 2 diabetes (T2D), skeletal muscle undergoes structural, function…
BACKGROUND: Glucagon-like peptide-1 (GLP-1) agonists, such as exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide, effectively manage type 2 diabetes by promoting insulin release, suppressing glucagon secretion, and enhancing glucose me…
BACKGROUND: Standard medications for opioid use disorder (MOUD) provide effective treatment pathways for recovery compared with no treatment or behavioral therapies alone. That said, people who continue to use non-prescribed opioids despite treatment…
PURPOSE: This study compared patient-reported compliance with package leaflet administration instructions of two glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for the treatment of type 2 diabetes (T2D): weekly injectable dulaglutide and daily…
PURPOSE OF REVIEW: Focused review highlighting ten select studies presented at the 2024 American Heart Association (AHA) Scientific Sessions. RECENT FINDING: Included studies assessed effects of intensive blood pressure control in patients with type…
Semaglutide and liraglutide are commonly used to address metabolic disorders, but differ in usage, clinical efficacy and safety profiles. Endocrinology medical staff are crucial in ensuring the appropriate administration, but their knowledge, attitud…
PURPOSE: Large telehealth companies and smaller aesthetic medicine providers used compounded semaglutide and tirzepatide to meet consumer demand for these drugs during their shortages. In this study, we estimate the documentation rate of compounded f…
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is increasingly used worldwide for its cardiometabolic benefits. However, it has recently been associated with nonarteritic anterior ischemic optic neuropathy (NAION). This report p…
OBJECTIVES: The use of glucagon-like peptide-1 (GLP-1) receptor agonists is increasingly common among orthopaedic patients, often prescribed for type 2 diabetes mellitus and obesity, which are frequent comorbidities. Recent studies have explored the…
INTRODUCTION: Glucagon-Like Peptide-1 Receptor (GLP1R) agonists have become widespread anti-obesity/diabetes pharmaceuticals in the United States. AIM: This article aimed to provide our current knowledge on the plausible mechanisms linked to the role…
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are at the forefront of treating the global health crisis of diabetes mellitus (DM) and obesity. However, the demand for GLP-1 RAs has far outstripped its supply and comes with a high monthly cost…
Recent pharmacological advances, illustrated by molecules such as semaglutide 2,4 mg and tirzepatide, have transformed the management of obesity. New innovative molecules, based in particular on key entero-pancreatic hormones such as glucagon-like pe…
AIMS: To evaluate the effectiveness of an online multidisciplinary weight loss service combining individualised semaglutide dosing with intensive behavioural therapy (IBT) in adults living with overweight or obesity. MATERIALS AND METHODS: This retro…